Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
40 CFR Part 792, Good Laboratory Practice Standards, covers the broader application of GLP standards for nonclinical laboratory studies conducted for assessing the safety or efficacy of chemical substances, including pesticides, under various regulatory programs overseen by the EPA. This regulation applies to nonclinical laboratory studies conducted for various purposes beyond pesticides, encompassing studies related to chemicals, drugs, food additives, and other substances regulated by the EPA. This part has a broader scope and is applicable to a wider range of substances and regulatory programs. It covers a more diverse range of nonclinical studies, including those related to chemical substances other than pesticides. This could include studies conducted for assessing the safety of industrial chemicals, pharmaceuticals, food additives, and other substances subject to EPA regulation. It operates across various regulatory programs within the EPA, reflecting a broader framework for ensuring the quality and reliability of nonclinical study data used in regulatory decision-making. While both 40 CFR Part 160 and 40 CFR Part 792 address GLP standards for laboratory studies, they differ significantly in terms of scope, applicability, and the specific regulatory context in which they operate. Part 160 is tailored to pesticide registration under FIFRA, whereas Part 792 is a more comprehensive framework applicable to a wider range of laboratory studies conducted for regulatory purposes across different EPA programs.
== Instrumentation == In the selected ion flow tube mass spectrometer, SIFT-MS, ions are generated in a microwave plasma ion source, usually from a mixture of laboratory air and water vapor. From the formed plasma, a single ionic species is selected using a quadrupole mass filter to act as "precursor ions" (also frequently referred to as primary or reagent ions in SIFT-MS and other processes involving chemical ionization). In SIFT-MS analyses, H3O+, NO+ and O2+ are used as precursor ions, and these have been chosen because they are known not to react significantly with the major components of air (nitrogen, oxygen, etc.), but can react with many of the very low level (trace) gases. The selected precursor ions are injected into a flowing carrier gas (usually helium at a pressure of 1 Torr) via a Venturi orifice (~1 mm diameter) where they travel along the reaction flow tube by convection. Concurrently, the neutral analyte molecules of a sample vapor enter the flow tube, via a heated sampling tube, where they meet the precursor ions and may undergo chemical ionization, depending on their chemical properties, such as their proton affinity or ionization energy. The newly formed "product ions" flow into the mass spectrometer chamber, which contains a second quadrupole mass filter, and an electron multiplier detector, which are used to separate the ions by their mass-to-charge ratios (m/z) and measure the count rates of the ions in the desired m/z range.
Corn (maize) became a staple food in the southeast United States and in parts of Europe. A disease that was characterized by dermatitis of sunlight-exposed skin was described in Spain in 1735 by Gaspar Casal. He attributed the cause to poor diet. In northern Italy it was named "pellagra" from the Lombard language (agra = holly-like or serum-like; pell = skin). In time, the disease was more closely linked specifically to corn. In the US, Joseph Goldberger was assigned to study pellagra by the Surgeon General of the United States. His studies confirmed a corn-based diet as the culprit, but he did not identify the root cause. Nicotinic acid was extracted from liver by biochemist Conrad Elvehjem in 1937. He later identified the active ingredient, referring to it as "pellagra-preventing factor" and the "anti-blacktongue factor." It was also referred to as "vitamin PP", "vitamin P-P" and "PP-factor", all derived from the term "pellagra-preventive factor". In the late 1930s, studies by Tom Douglas Spies, Marion Blankenhorn, and Clark Cooper confirmed that nicotinic acid cured pellagra in humans. The prevalence of the disease was greatly reduced as a result. Nicotinic acid was initially synthesized by oxidizing nicotine with potassium chromate and sulfuric acid. Hence, in 1942, when flour enrichment with nicotinic acid began, a headline in the popular press said "Tobacco in Your Bread." In response, the Council on Foods and Nutrition of the American Medical Association approved of the Food and Nutrition Board's new names niacin and niacin amide for use primarily by non-scientists.
=== Positions on trans identity, accusations of transphobia and connections to the far-right === On January 22, 2020, after a collage was posted in the city of Montpellier calling for the inclusion of trans women in the feminist movement with the slogan "sisters not cisTERF" (a pun on "cis", i.e. not trans, and "TERF", meaning "transgender-exclusionary radical feminist"), she commented she felt trans activism had become too important in the collage movement and within feminism on Twitter. She stated in particular that being a woman is a question of biology and that the activism of trans women was insulting and reduced women to a set of patriarchal stereotypes such as makeup and clothes. She denied trans women's womanhood, stating: "Throughout time, men have tried to silence women by silencing their revolts. Today, they do it from the inside by infiltrating our struggles". She refuses trans-inclusive language such as "people with vulvas". Her positions have led to her being considered a "TERF" by intersectional feminists. Following these statements, the Instagram account Collages Féminicides Paris distanced itself from her comments: "Discrimination has always been condemned […]. We're talking about the exclusion of a part of women from the struggle; transphobia is not a debate." She became increasingly marginalized in the collage movement, months after leaving its leadership. She was the subject of numerous insults on social networks, so much so that the collective reacted and specified that it repudiates any "killing rhetoric".
Sources: en.wikipedia.org
For convenience, three different views of the data are available on Wikipedia: two sets of "segmented tables", and a single "unitized table (all elements)". The unitized table allows easy visualization of proton/neutron-count trends but requires simultaneous horizontal and vertical scrolling. The segmented tables permit easier examination of a particular chemical element with much less scrolling. Links are provided to quickly jump between the different sections.
== Charity == Through its fundraiser "Drink One for Dane", Dutch Bros Coffee donates to the Muscular Dystrophy Association. Its other annual charitable initiatives include Dutch Luv, which benefits local food banks, and Buck for Kids, which supports local youth organizations, including chapters of the Boys & Girls Clubs of America.
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met (RPKPQQFFGLM) with an amide group at the C-terminus. Substance P is released from the terminals of specific sensory nerves. It is found in the brain and spinal cord and is associated with inflammatory processes and pain.
The Trump administration took the unusual step of subjecting approximately 50 members of the US military's Joint Chiefs of Staff to polygraph tests over leaks to journalists, including information about how the war has resulted in a shortage of critical munitions. Early attacks on US bases caused logistics issues in US aircraft carrier USS Abraham Lincoln. The Pentagon has transferred weapons stored in Asia and Europe to replenish stockpiles in the Middle East. Still, missile interceptors shortage reportedly persuaded Trump to call off a planned major attack on Iran. The Trump administration blames the shortage on Joe Biden giving too many weapons to Ukraine. On 17 September, Lockheed Martin received the first batch of Patriot interceptor parts from General Motors less than a month after the two companies signed a manufacturing agreement, in a success for the Pentagon's push for faster weapon production, particularly the Patriot missile defense system, as it remained one of the world's most sought-after weapons for the war and Russia's war in Ukraine.
== Further reading == Jack Hartnell, "Wording the Wound Man", British Art Studies (6), 2017: http://britishartstudies.ac.uk/issues/issue-index/issue-6/wound-man Cahill, Patricia A. Wound-man Walking: Visceral History and Traumatized Bodies in A Larum for London Unto the Breach: Martial Formations, Historical Trauma, and the Early Modern Stage
Sources: en.wikipedia.org
=== Benefits to females === Among numerous species in the animal kingdom, females may benefit from absorbing nutrients and proteins from seminal fluid for food, antiviral and antibacterial properties, and enhanced fertilisation. In humans, seminal fluid provides anti-viral activity towards herpes simplex virus and can transfer anti-microbial peptides cathelicidin and lactoferrin. In birds and mammals, mutualistic bacteria such as Lactobacillus have been detected in fluid transferral. A study on the effect of semen in male-to-female transmission of HIV, in both humans and non-human primates (rhesus macaques), noted that regular intravaginal exposure to a healthy male's semen modulates the microenvironment in the female reproductive tract (FRT), and, paradoxically, improves the resistance in females against acquiring HIV by activating their bodies' anti-HIV mechanisms.
== Parasites == Parasites include Plasmodium berghei (for which it also serves as a vector), and the bioinsecticides/entomopathogenic fungi Metarhizium robertsii and Beauveria bassiana. All three of these parasites combine with insecticides to reduce fitness – see § Insecticides below. CRISPR/Cas9 and U6-gRNA are increasingly (as of 2020) being used together for knockout experiments in mosquitoes. Dong et al., 2018 develops and presents a new U6-gRNA+Cas9 technique in An. gambiae, and utilizes it to knock out fibrinogen related protein 1 (FREP1), thereby severely reducing infection of the mosquito by P. berghei and P. falciparum. However this also demonstrates the centrality of FREP1 to the insect's success, impairing all measured activities across all life stages. Yang et al., 2020 uses the Dong method to do the same with mosGILT, also severely reducing Plasmodium infection of the mosquito but also finding a vital life process is impaired, in mosGILT's case ovary development.
Nussbaum, Louis-Frédéric and Käthe Roth. (2005). Japan encyclopedia. Cambridge: Harvard University Press. ISBN 978-0-674-01753-5; OCLC 58053128 Rickman, J. (2003). Sunset of the samurai. Military History. August, 42–49. Shinsengumihq.com, (n.d.). No sleep, no rest: Meiji law enforcement. Retrieved August 5, 2008. Vos, F., et al., Meiji, Japanese Art in Transition, Ceramics, Cloisonné, Lacquer, Prints, Organized by the Society for Japanese Art and Crafts, 's-Gravenhage, the Netherlands, Gemeentemuseum, 1987. ISBN 90-70216-03-5
for the synthesis of S-Nitrosoglutathione see Hart, T.W., 1985. Some observations concerning the S-nitroso and S-phenylsulphonyl derivatives of L-cysteine and glutathione. Tetrahedron Letters, 26(16), pp.2013-2016.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.